ArticleThe Journal of infectious diseases2017
Different Challenges in Eliminating HPV16 Compared to Other Types: A Modeling Study.
Article in The Journal of infectious diseases, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Penile HPV prevalence among high-risk men in Sri Lanka: baseline insight for HPV prevention strategies in a lower-middle-income country.Infectious agents and cancer · 2026Article
- Strong Herd Effects of Human Papillomavirus Vaccination.The Journal of infectious diseases · 2025Article
- Population-Based Age-Period-Cohort Analysis of Declining Human Papillomavirus Prevalence.The Journal of infectious diseases · 2025Article
- Vaccination and screening strategies to accelerate cervical cancer elimination in Norway: a model-based analysis.British journal of cancer · 2024Article
- Gender neutral HPV vaccination programs: Reconsidering policies to expand cancer prevention globally.Frontiers in public health · 2023Review
- Observational
- Differing Age-Specific Cervical Cancer Incidence Between Different Types of Human Papillomavirus: Implications for Predicting the Impact of Elimination Programs.American journal of epidemiology · 2021Article
- From cervical cancer elimination to eradication of vaccine-type human papillomavirus: Feasibility, public health strategies and cost-effectiveness.Preventive medicine · 2021Article
- Diversity of human papillomavirus typing among women population living in rural and remote areas of Brazilian territory.Papillomavirus research (Amsterdam, Netherlands) · 2019Article
- Regional variations in human papillomavirus prevalence across time in NHANES (2003-2014).Vaccine · 2019Article
- Potential effectiveness of prophylactic HPV immunization for men who have sex with men in the Netherlands: A multi-model approach.PLoS medicine · 2019Article
- Impacts of human papillomavirus vaccination for different populations: A modeling study.International journal of cancer · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Background: Human papillomavirus (HPV) vaccination is still not reaching many high-risk populations. HPV16/18 vaccines offer cross-protection against other types, for example, HPV45. Both direct vaccine efficacy and indirect herd protection contribute to vaccination effectiveness. Methods: We used a dynamic transmission model, calibrated to cervical screening data from Italy, to estimate vaccination effectiveness against HPV16 and HPV45 infection, assuming for HPV45 either 95% or lower cross-protection. Results: Basic reproductive number was smaller (2.1 vs 4.0) and hence vaccine effectiveness and herd protection stronger for HPV45 than for HPV16. The largest difference in the reduction of infection prevalence in women <35 years old was found at 70% coverage in girls-only vaccination programs (99% vs 83% for total protection for HPV45 and HPV16, respectively, mainly owing to stronger herd protection, ie, 37% vs 16%). In gender-neutral vaccination, the largest difference was at 40% coverage (herd protection, 54% vs 28% for HPV16 and HPV45, respectively). With ≥80% coverage, even 50% cross-protection would reduce HPV45 by ≥94%. Conclusions: The characteristics of individual high-risk HPV types strongly influence herd protection and determine the level of coverage and cross-protection required to reduce or eliminate the infection through HPV vaccination. HPV16 infection and related cancers are the most difficult to eliminate.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.